An Exploratory Study to Assess the 24-hour Intraocular Pressure (IOP) Lowering Characteristics, Duration of Action and Safety of DE-126 ophthalmic solution 0.002% versus Latanoprost ophthalmic solution 0.005% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Sepetaprost (Primary) ; Latanoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Santen Inc
- 30 Jan 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 04 Dec 2022 This trial has been completed in Austria according to European Clinical Trials Database record.
- 18 May 2021 New trial record